Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of
Report: (Date of earliest event reported): April 3, 2008
CLEVELAND
BIOLABS, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32954
|
|
20-0077155
|
(State
or other jurisdiction
of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
73
High Street, Buffalo, New York 14203
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (716) 849-6810
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
On
April
3, 2008, Cleveland BioLabs, Inc. (the “Company”) issued a press release
announcing that it has been awarded a contract by the U.S. Department of Defense
for up to approximately $8.9 million to fund the advanced development of the
Company’s lead product candidate, Protectan CBLB502, as a medical radiation
countermeasure. A copy of the press release is attached as Exhibit
99.1.
Item 9.01
|
Financial
Statements and Exhibits
|
(d)
Exhibits
Exhibit
No.
|
|
Exhibit
|
|
|
|
99.1
|
|
Press
Release dated April 3, 2008.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
CLEVELAND
BIOLABS,
INC |
|
|
|
Date: April
3, 2008 |
By: |
/s/
Michael
Fonstein |
|
Michael
Fonstein
President
and Chief Executive Officer
|
|
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Exhibit
|
|
|
|
99.1
|
|
Press
Release dated April 3, 2008.
|